Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
28.23
-0.35 (-1.22%)
At close: Mar 24, 2026, 4:00 PM EDT
28.23
0.00 (0.00%)
After-hours: Mar 24, 2026, 4:10 PM EDT
Assembly Biosciences Revenue
In the year 2025, Assembly Biosciences had annual revenue of $72.30M with 153.52% growth. Assembly Biosciences had revenue of $42.47M in the quarter ending December 31, 2025, with 477.26% growth.
Revenue (ttm)
$72.30M
Revenue Growth
+153.52%
P/S Ratio
6.19
Revenue / Employee
$990,452
Employees
73
Market Cap
447.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.30M | 43.78M | 153.52% |
| Dec 31, 2024 | 28.52M | 21.36M | 298.16% |
| Dec 31, 2023 | 7.16M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 6.25M | -72.85M | -92.09% |
| Dec 31, 2020 | 79.11M | 63.14M | 395.55% |
| Dec 31, 2019 | 15.96M | 1.16M | 7.83% |
| Dec 31, 2018 | 14.80M | 5.79M | 64.14% |
| Dec 31, 2017 | 9.02M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Maravai LifeSciences Holdings | 185.74M |
| Fulcrum Therapeutics | 80.00M |
| Entrada Therapeutics | 25.42M |
| Absci | 2.82M |
| Upstream Bio | 2.80M |
| Altimmune | 41.00K |
| Lyell Immunopharma | 36.00K |
ASMB News
- 4 days ago - Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development - Seeking Alpha
- 5 days ago - Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 3 months ago - Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - Business Wire
- 3 months ago - Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript - Seeking Alpha
- 3 months ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 4 months ago - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 4 months ago - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - GlobeNewsWire
- 5 months ago - Assembly Biosciences Announces Upcoming Investor Conference Participation - GlobeNewsWire